ACAD
Price
$15.79
Change
+$0.79 (+5.27%)
Updated
Nov 6 closing price
116 days until earnings call
SAGE
Price
$5.95
Change
+$0.01 (+0.17%)
Updated
Nov 6 closing price
104 days until earnings call
Ad is loading...

ACAD vs SAGE

Header iconACAD vs SAGE Comparison
Open Charts ACAD vs SAGEBanner chart's image
ACADIA Pharmaceuticals
Price$15.79
Change+$0.79 (+5.27%)
Volume$2.11M
CapitalizationN/A
Sage Therapeutics
Price$5.95
Change+$0.01 (+0.17%)
Volume$786.12K
CapitalizationN/A
View a ticker or compare two or three
ACAD vs SAGE Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ACAD vs. SAGE commentary
Nov 07, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Buy and SAGE is a StrongSell.

COMPARISON
Comparison
Nov 07, 2024
Stock price -- (ACAD: $15.79 vs. SAGE: $5.95)
Brand notoriety: ACAD and SAGE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 140% vs. SAGE: 111%
Market capitalization -- ACAD: $2.62B vs. SAGE: $363.98M
ACAD [@Biotechnology] is valued at $2.62B. SAGE’s [@Biotechnology] market capitalization is $363.98M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileSAGE’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • SAGE’s FA Score: 1 green, 4 red.
According to our system of comparison, SAGE is a better buy in the long-term than ACAD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish while SAGE’s TA Score has 3 bullish TA indicator(s).

  • ACAD’s TA Score: 5 bullish, 4 bearish.
  • SAGE’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, ACAD is a better buy in the short-term than SAGE.

Price Growth

ACAD (@Biotechnology) experienced а +6.91% price change this week, while SAGE (@Biotechnology) price change was -7.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.98%. For the same industry, the average monthly price growth was +13.13%, and the average quarterly price growth was +11.75%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 03, 2025.

SAGE is expected to report earnings on Feb 19, 2025.

Industries' Descriptions

@Biotechnology (+0.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.62B) has a higher market cap than SAGE($364M). ACAD YTD gains are higher at: -49.569 vs. SAGE (-72.543). ACAD has higher annual earnings (EBITDA): 34.3M vs. SAGE (-371.15M). SAGE has more cash in the bank: 569M vs. ACAD (501M). SAGE has less debt than ACAD: SAGE (10.3M) vs ACAD (57.7M). ACAD has higher revenues than SAGE: ACAD (891M) vs SAGE (106M).
ACADSAGEACAD / SAGE
Capitalization2.62B364M720%
EBITDA34.3M-371.15M-9%
Gain YTD-49.569-72.54368%
P/E Ratio83.11N/A-
Revenue891M106M841%
Total Cash501M569M88%
Total Debt57.7M10.3M560%
FUNDAMENTALS RATINGS
ACAD vs SAGE: Fundamental Ratings
ACAD
SAGE
OUTLOOK RATING
1..100
1468
VALUATION
overvalued / fair valued / undervalued
1..100
81
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7997
PRICE GROWTH RATING
1..100
7491
P/E GROWTH RATING
1..100
6597
SEASONALITY SCORE
1..100
85n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAGE's Valuation (24) in the Pharmaceuticals Other industry is somewhat better than the same rating for ACAD (81) in the Biotechnology industry. This means that SAGE’s stock grew somewhat faster than ACAD’s over the last 12 months.

SAGE's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as ACAD (100) in the Biotechnology industry. This means that SAGE’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (79) in the Biotechnology industry is in the same range as SAGE (97) in the Pharmaceuticals Other industry. This means that ACAD’s stock grew similarly to SAGE’s over the last 12 months.

ACAD's Price Growth Rating (74) in the Biotechnology industry is in the same range as SAGE (91) in the Pharmaceuticals Other industry. This means that ACAD’s stock grew similarly to SAGE’s over the last 12 months.

ACAD's P/E Growth Rating (65) in the Biotechnology industry is in the same range as SAGE (97) in the Pharmaceuticals Other industry. This means that ACAD’s stock grew similarly to SAGE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACADSAGE
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
Momentum
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
76%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 16 days ago
73%
Bearish Trend 4 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
88%
Aroon
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
81%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SAGE
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMOPX34.311.29
+3.91%
Patient Opportunity C
JMCGX22.980.64
+2.86%
Jacob Discovery Fd Inv
PSLGX153.252.84
+1.89%
Putnam Sustainable Leaders R6
JTKNX14.46N/A
N/A
JHancock Global Thematic Opps NAV
MNBWX20.54N/A
N/A
Manning & Napier Pro-Blend Extnd Term W

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with VRTX. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+5.27%
VRTX - ACAD
47%
Loosely correlated
-1.27%
DNLI - ACAD
44%
Loosely correlated
+6.98%
CCCC - ACAD
43%
Loosely correlated
-1.97%
ADCT - ACAD
43%
Loosely correlated
+4.92%
FOLD - ACAD
43%
Loosely correlated
-4.34%
More